Correlation Between the Efficacy of Neoadjuvant Chemotherapy Combined With Immunotherapy of Operable Thoracic Esophageal Squamous Cell Carcinoma and the Metabolites of Intestinal Flora

This study collects stool, blood, and tumor tissue samples from patients with locally advanced esophageal cancer after receiving Sintilimab and chemotherapy to explore the efficacy and intestinal microbes of chemotherapy combined with neoadjuvant immunotherapy for locally advanced operable thoracic esophageal squamous cell carcinoma The main purpose is the relationship between its metabolites, and it will also explore the changes of intestinal flora diversity and metabolites before and after esophageal squamous cell carcinoma chemotherapy combined with immune neoadjuvant therapy

本研究采集局部晚期食管癌患者接受信迪利单抗（Sintilimab）联合化疗后的粪便、血液与肿瘤组织样本，旨在探索化疗联合新辅助免疫治疗针对局部晚期可手术胸段食管鳞状细胞癌的疗效、肠道微生物与代谢物之间的关联；同时本研究还将探究食管鳞状细胞癌患者接受化疗联合免疫新辅助治疗前后，肠道菌群多样性及代谢物的变化情况。